Update on stroke prevention
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
It is now well recognized that stroke-prone individuals can be identified in the majority of instances and that effective preventive therapy is available. Cumulative risk factors enhance the potential for stroke. The challenge is to effectively intervene to substantially reduce stroke risk.
- American Heart Association. Heart Disease and Stroke Statistics-2004 Update. American Heart Association, Dallas, TX, 2003.
- Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992;49:857–863.
- Wolf PA, D’Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA 1998; 259(7):1025–1029. CrossRef
- Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke 2002;33:862–875. CrossRef
- Rimm EB, Willet WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359–336. CrossRef
- Rodriguez BL, D’Agostino R, Abbott, RD, et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study-a comparison of incidence and risk factor effects. Stroke 2002;33(1):230–236. CrossRef
- Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004;35:1024–1033. CrossRef
- Sokol SI, Portnay EL, Curtis JP, et al. Modulation of the reninangiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004;63:208–213.
- Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial. Stroke 2003;34:2333–2338. CrossRef
- The Heart Outcomes prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145–153. CrossRef
- Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311):995–1003. CrossRef
- Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 2003;163:669–676. CrossRef
- Hart RG. Atrial fibrillation and stroke prevention. N Engl J Med 2003;349:1015–1016. CrossRef
- Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019–1026. CrossRef
- van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003;163:936–943. CrossRef
- Kelley RE, Minagar A. Cardioembolic stroke: an update. S Med J 2003;96:343–349. CrossRef
- Mohr J, Thompson JLP, Lazar RM, et al. for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345:1444–1451. CrossRef
- Levine SR, Brey RL, Tilley BC, et al. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291(5):576–584. CrossRef
- Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.
- Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events. Arch Neurol. 2002;57:326–332. CrossRef
- Taylor DW, Barnett HJM, Haynes RB, et al. for the ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. Lancet 1999;353:2179–2184. CrossRef
- Chen ZM, Sandercock P, Pan HC, et al. on behalf of the CAST and IST collaborative group. Indications for early aspirin use in acute ischemic stroke. A combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 2000;31:1240–1249.
- Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501–507. CrossRef
- Weisberg LA for the Ticlopidine Aspirin Stroke Study Group. The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Prevention Study. Neurology 1993;43:27–31.
- Gorelick PB, Richardson D, Kelly M, et al. for the African American Antiplatelet Stroke Prevention Study (AAASPS) Investigators. JAMA 2003;289:2947–2957. CrossRef
- CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329–1339. CrossRef
- Diener HC, Bogousslavsky J, Brass LM, et al. on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:331–337. CrossRef
- Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13. CrossRef
- North American Symptomatic Carotid Endarterectomy Trialists’ Collaborative Group. The final results of the NASCET trial. N Engl J Med 1998;339:1415–1425. CrossRef
- European Carotid Surgery Trialists’ Collaborative Group. Randomized trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379–1387. CrossRef
- Rothwell PM, Gutnikov SA, Warlow CP. Reanalysis of the final results of the European Carotid Surgery Trial. Stroke. 2003;34:514–523. CrossRef
- Rothwell PM, Eliasziw M, Gutnikov SA, et al. for the Carotid Endarterectomy Trialists’ Collaboration. Analysis of pooled data from the randomized controlled trials of endarterectomy for symptomatic carotid stenosis Lancet. 2003;361:107–116. CrossRef
- Asymptomatic Carotid Atherosclerosis Study Group. Carotid endarterectomy for patients with asymptomatic internal carotid artery stenosis. JAMA. 1995;273:1421–1428. CrossRef
- Halliday A, Mansfield A, Marro J, et al. MCR Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trial. Lancet. 2004;363:1491–1502. CrossRef
- Brott TG, Brown RD, Meyer FB, Miller DA, Cloft HJ, Sullivan TM. Carotid revascularization for prevention of stroke: carotid endarterectomy and carotid artery stenting. Mayo Clin Proc. 2004;79(9):1197–1208. CrossRef
- Update on stroke prevention
Volume 31, Issue 2 , pp 113-118
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links